seed funding for novel, high-risk, high-reward translational research on neurodegenerative diseases of aging up to $300,000 over up to 18 months.

seed funding for novel, high-risk, high-reward translational research on neurodegenerative diseases of aging up to $300,000 over up to 18 months.

goal: to provide funding for translational research that will accelerate the development of therapeutics for neurodegenerative diseases of aging.

funding: a maximum of $1,500,000 over up to 3 years per project. encouraging applications at all funding levels from $300,000 to $1,500,000, without need for preliminary data.

applicant eligibility: eligible principal applicants must be researchers working in canada at least 30% of the time at or above the level of assistant professor or equivalent, and be affiliated with a canada revenue agency-qualified donee institution located in canada. co-applicants/collaborators must be at the post-doctoral level or above and can be working outside canada.

applicants may appear in any role on any number of projects.

project eligibility: projects must meet the following conditions to be eligible:

• be translational research (excluding clinical trials and clinical trial sub-studies) that accelerates the development of therapeutics for neurodegenerative diseases of aging.
  • clinical trials and clinical trial sub-studies should be submitted to the early-phase clinical trials or rapid response programs; however other translational research using humans or human samples/data is in scope.
• be the development of a therapeutic and/or tool and/or select complementary approaches (please refer to the program details for more information on complementary approaches that are in scope)

the fy20 defense appropriations act provides funding to the department of defense gulf war illness research program (gwirp) to support research addressing gulf war illness (gwi) pathobiology, diagnosis, and treatment.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate, manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 gwirp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

applications submitted to the fy20 gwirp must address one or more of the following overarching challenges:

• treatments: eliminate the health consequences associated with gwi and revolutionize treatment
• diagnosis: better define and diagnose gwi
• subtyping: distinguish symptom clusters to better target treatments, identify underlying causes, and elucidate differences in severity
• determinants: validate exposures associated with gwi and impacts on organs and systems
• consequences: determine whether gwi is associated with greater risk for developing other disease states including neurological diseases, cancers, or other life-threatening and severely debilitating conditions
• communicate: help veterans, their caregivers, researchers and health care providers communicate effectively about gwi, its symptoms, and potential treatments

https://cdmrp.army.mil/funding/gwirp

idea award – preproposal due may 29, 2020

independent investigators at all academic levels

• supports innovative, high-risk/high-reward research in the earliest stages of development that will contribute to markers or treatments for gulf war illness (gwi).
• emphasis is on impact and innovation; applications must articulate how results will lead to a clinical impact for veterans with gwi, even if a clinical impact is not an immediate outcome.
• preliminary data not required.
• clinical trials not allowed.
• submission of a pre-application is required; application submission is by invitation only.
• biorepository contribution option:
• supports additional costs associated with submission of samples and data to the gwirp-supported boston biorepository, recruitment, and integrative network
• applicants must submit a biorepository contribution statement providing a detailed accounting of proposed costs and a commitment to work with the gwirp-supported biorepository resource network.
• application to this option is not a requirement for idea award submission.
• maximum funding of $150,000 for direct costs (plus indirect costs)
• maximum funding of $170,000 for direct costs with the biorepository contribution option (plus indirect costs).
• maximum period of performance is 2 years

research advancement award – preproposal due may 29, 2020

independent investigators at all academic levels

• supports applied research in gwi that is aimed at continued expansion and validation of markers and treatments that are supported by evidence in the gwi field. 
• preliminary data in field of gwi and other supporting information are required.
• applications must articulate how results will lead to a clinical impact for veterans with gwi, even if a clinical impact is not an immediate outcome.
• clinical trials not allowed.
• submission of a pre-application is required; application submission is by invitation only.
• biorepository contribution option:
• supports additional costs associated with submission of samples and data to the gwirp supported biorepository resource network.
• applicants must submit a biorepository contribution statement providing a detailed accounting of proposed costs and a commitment to work with the gwirp-supported biorepository resource network.
• application to this option is not a requirement for research advancement award submission.
• maximum funding of $625,000 for direct costs (plus indirect costs)
• maximum funding of $645,000 for direct with the biorepository contribution option (plus indirect costs).
• maximum period of performance is 3 years

clinical evaluation award – preproposal due may 29, 2020

independent investigators at all academic levels

• supports translational of validated gwi research, including qualified and replicated preclinical findings, to a gulf war veteran population.
• statistically powered biomarker trials with the potential to validate use of biomarkers as clinical endpoints or proof-of-concept intervention trials (e.g., pilot, first in human, phase i-iia) are encouraged under this funding opportunity.
• preliminary data are required.
• funding for this award mechanism must support research in a gulf war veteran population.  proof of availability and access to necessary cohort(s) and/or critical reagents must be provided.
• submission of a pre-application is required; application submission is by invitation only.

biorepository contribution option:

• supports additional costs associated with submission of samples and data to the gwirp-supported biorepository resource network.
• applicants must submit a biorepository contribution statement providing a detailed accounting of proposed costs and a commitment to work with the gwirp-supported biorepository resource network.
• application to this option is not a requirement for clinical evaluation award submission.

clinical consortium collaboration option:

• supports additional costs associated with collaboration with the gwirp- supported gulf war illness clinical trials and interventions consortium (gwictic).
• applicants must submit a clinical consortium collaboration statement providing a detailed accounting of proposed costs and clearly articulating the qualifications of the research team and institution to participate as a new clinical research site in the consortium.
• application to this option is not a requirement for clinical evaluation award submission.
  • maximum funding of $1,500,000 for direct costs (plus indirect costs).
  • maximum funding of $1,520,000 for direct costs with the biorepository contribution option (plus indirect costs).
  • maximum funding of $1,700,000 for direct costs with the clinical consortium collaboration option (plus indirect costs).
  • maximum period of performance is 3 years

therapeutic/biomarker trial award – preproposal due may 29, 2020

independent investigators at all academic levels

• supports large-scale, pivotal (phase iib or iii) trials that revolutionize the clinical management of gwi.
• proposed research should lead to an approach that is fundamentally better than interventions already approved or in clinical development.
  • objective biomarkers to measure the biological effect of an investigational therapeutic or predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual gulf war veteran or gulf war veteran subgroup must be included in the trial design.
  • investigators must have experience in successfully leading large-scale projects and demonstrated the ability to implement a clinical project successfully.
  • funding must be used to support a clinical trial.
  • preproposal submission is required; application submission is by invitation only.
  • biorepository contribution option:
  • supports additional costs associated with submission of samples and data to the gwirp-supported biorepository resource network
  • application must submit a biorepository contribution statement providing a detailed accounting of proposed costs and a commitment to work with the gwirp=supported biorepository resource network.
  • application to this option is not a requirement for therapeutic/biomarker trial award submission.
  • clinical consortium collaboration option:
  • supports additional costs associated with collaboration with the gwirp-supported gulf war illness clinical trials and interventions consortium
  • applicants must submit a clinical consortium collaboration statement providing a detailed accounting of proposed costs and clearly articulates the qualifications of the research tea and institution to participate as a new clinical research site in the consortium.
  • application to this option is not a requirement for therapeutic/biomarker trial award submission.
  • funding must be used to support a clinical trial.
    • maximum funding of $5,000,000 for direct costs (plus indirect costs)
    • maximum funding of $5,020,000 for direct costs with the biorepository contribution option (plus indirect costs).
    • maximum funding of $5,500,000 for direct costs with the clinical consortium collaboration option (plus indirect costs).
    • maximum period of performance is 4 years

patient-provider and health communications award – preproposal due may 29, 2020

independent investigators at all academic levels

• supports projects aimed at tools and processes to raise awareness of gwi research and clinical findings within communities, including veterans with gwi and/or their caregivers or advocates, healthcare providers who serve veterans with gwi, or public health professional relevant to veterans with gwi.
• maintenance and sustainment of the dissemination effort past the award period for continued awareness of gwi research and clinical findings to diverse audiences is an important review criterion.
• must include a description of evaluation metrics and tracking to assist in measuring the success of the communication tool process.
• must include at least one consumer gwi advocate, who will be integral throughout the planning and implementation of the research project.
• clinical trials not allowed.
• preproposal submission is required; application submission is by invitation only.
  • maximum funding of $600,000 for direct costs (plus indirect costs)
  • maximum period of performance is 3 years

new investigator award – preproposal due may 29, 2020

investigators may apply under one of the following three eligibility categories:

transitioning postdoctoral fellow: senior postdoctoral fellows with at least 3 years of postdoctoral training

early-career investigator: independent investigators within 5 years since their last training position

new gwi researcher: established independent investigators who have received less than $300,000 in federally funded, non-mentored gwi research

• encourages applications from early-stage and established investigators new to the field of gwi research.
• previous experience in gwi research is not required; however, collaborations with experienced gwi researchers are strongly encouraged.
• preliminary data not required.
• clinical trials not allowed.
  • preproposal submission is required; application submission is by invitation only.
  • biorepository contribution option:
  • supports additional costs associated with submission of samples and data to the gwirp-supported biorepository resource network.
  • applicants must submit a biorepository contribution statement providing a detailed accounting of proposed costs and a commitment to work with the gwirp-supported biorepository resource network.
  • application to this option is not a requirement for new investigator award submission.
    • maximum funding of $500,000 for direct costs (plus indirect costs)
    • maximum funding of $520,000 for direct costs with the biorepository contribution option (plus indirect costs)
    • the maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the gwirp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the fy20 defense appropriations act provides funding to the department of defense lung cancer research program (lcrp) to support innovative, high-impact lung cancer research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 lcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

applications submitted to the fy20 lcrp must address one or more of the following areas of emphasis:

*identify innovative strategies for the screening and early detection of lung cancer.

*understand the molecular mechanisms of initiation and progression to lung cancer.

*identify innovative strategies for prevention of the occurrence of lung cancer.

*identify innovative strategies for the treatment of lung cancer.

*identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.

*develop or optimize prognostic or predictive markers to assist with therapeutic decision-making.

*understand mechanisms of resistance to treatment (primary and secondary).

*understand contributors to lung cancer development other than tobacco.

*identify innovative strategies for lung cancer care delivery (disparities/clinical management/ surveillance/symptom management).

relevance to military health: the lcrp seeks to support research that is relevant to the healthcare needs of military service members, veterans, and their families. relevance to military health will be considered in determining relevance to the mission of the dhp and fy20 lcrp during programmatic review.   investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:

*use of military or veteran populations, biospecimens, data/databases, or programs in the proposed research

*collaboration with department of defense or department of veterans affairs (va) investigators

*description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population

*explanation of how the project addresses an aspect of lung cancer that has direct relevance to military service members, veterans, or other military health system beneficiaries, including environmental exposures other than tobacco

https://cdmrp.army.mil/funding/lcrp

career development award – letter of intent due july 15, 2020

• independent investigators the level of assistant professor, instructor, or equivalent; must be within 5 years of first faculty appointment.
• must not have received a career development award previously from any program within the congressionally directed medical research programs.
• must not have received more than $300,000 in total direct costs for previous or concurrent lung cancer research as a pi of one or more federally or privately funded, non-mentored, peer-reviewed grants.
• mentor
• at or above the level of associate professor (or equivalent).
• must have a strong publication and funding record in lung cancer research.
• supports early-career, independent researchers to conduct research under the mentorship of an experienced lung cancer researcher.
• clinical trials not allowed.
• preliminary data discouraged.
• military relevance strongly encouraged.
• maximum funding of $250,000 in direct costs (plus indirect costs).
• period of performance should not exceed 2 year.

clinical translational research partnership award – letter of intent due july 15, 2020

investigators at or above the level of assistant professor (or equivalent).

• supports translational studies that include a clinical trial.
• intended to fund partnerships between clinicians and laboratory scientists that accelerate ideas in lung cancer into clinical applications.
• one partner is strongly encouraged to be from either a military treatment facility of a department of veterans affairs medical center.
• non-traditional partnerships are encouraged.
• preliminary lung cancer relevant data required.
• military relevance strongly encouraged.
• patient research advocate involvement encouraged.
• maximum combined funding of $1,200,000 in direct costs (plus indirect costs).
• period of performance should not exceed 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the lcrp or other cdmrp-administered programs, please visit the cdmrp website.

point of contact:

cdmrp help desk

301-682-5507

help@ebrap.org

e.w.r. steacie memorial fellowships recognize early-stage academic researchers in the natural sciences and engineering and support them to enhance their research capacity, so that they can become leaders in their field and inspire others. nserc awards up to six steacie fellowships each year. steacie fellowships honour the memory of dr. edgar william richard steacie.

the fy20 defense appropriations act provides $40 million (m) to the department of defense spinal cord injury research program (scirp) to support innovative, high-impact spinal cord injury (sci) research¹.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 scirp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

applications submitted to the fy20 scirp must address one or more of the following focus areas:

• preserving and protecting spinal cord tissue at time of injury for improved neurologic outcomes
• identifying and validating biomarkers for diagnosis, prognosis, and for evaluation of treatment efficacies (translational research award and investigator-initiated research award only)
• bowel, genitourinary, cardiopulmonary dysfunction, and neuropathic pain
• psychosocial issues relevant to people with sci, their families, and/or their care partners

rehabilitation and regeneration—maximizing the function of the residual neural circuitry, including harnessing

• neuroplasticity and recovery to improve function after sci

https://cdmrp.army.mil/funding/scirp

clinical trial award – preproposal due may 21, 2020

investigators at all academic levels (or equivalent)

• preproposal is required; application submission is by invitation only.
• fund phase 0, i, or ii clinical trials with the potential to have a major impact on treatment or management of sci.
• applications must include at least two individuals with lived sci experience as members of the research team.
• preclinical data required for all clinical trial applications.
• maximum funding of $3m for direct costs (plus indirect costs)
• maximum period of performance is 4 years

translational research award – preproposal due may 21, 2020

investigators at all academic levels (or equivalent)

• preproposal is required; application submission is by invitation only.
• fund translational research studies that accelerate the movement of promising ideas in sci research into clinical applications.
• applications must include at least one individual with lived sci experience as a member of the research team.
• the scirp tra may include a pilot clinical trial as part of the proposed research where limited clinical testing of a novel intervention or device is necessary to inform the next step in the continuum of translational research.
• preliminary data required.
  • maximum funding of $1.25m for direct costs (plus indirect costs)
  • maximum period of performance is 3 years

investigator-initiated research award – preproposal due may 21, 2020

investigators at all academic levels (or equivalent)

• preproposal is required; application submission is by invitation only.
• fund and phase of sci-related research from basic through translational that has the potential to make an important contribution to sci research, patient care, and/or quality of life.
• clinical trials not allowed.
• preliminary data required.
• maximum funding of $500,000 for direct costs (plus indirect costs)
• maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the scirp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507
help@ebrap.org

the fy20 defense appropriations act provides funding to the department of defense peer reviewed cancer research program (prcrp) to support innovative, high-impact cancer research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 prcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

congressionally directed topic areas:  the prcrp appropriation of $110,000,000 will provide funds for research into cancers not addressed in the breast, pancreatic, prostate, ovarian, kidney, lung, melanoma, and rare cancer research programs.  to be considered for funding, applications for the fy20 prcrp must address at least one of the fy20 prcrp topic areas as directed by congress.  research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, melanoma, pancreatic, rare cancer, or ovarian cancer will not be accepted. the inclusion of the individual rare cancer research program shall not prohibit the prcrp from funding the below mentioned cancers or cancer subtypes that may be rare by definition.

the fy20 prcrp topic areas are:

^†as derived from the nci dictionary of cancer terms (http://www.cancer.gov/publications/dictionaries/cancer-terms).  immunotherapy is a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer.  cancers studied under this topic area should be within the scope of the congressional language and the intent of the program announcement(s).

*national cancer institute (nci) definition of adolescents and young adults (https://www.cancer.gov/types/aya) is people between 15-39 years of age.  cancers studied under this topic area should be within the scope of the congressional language and the intent of the program announcement(s). research should be targeted toward children (ages 0-14 years), adolescents (ages 15-24 years), and/or young adults (ages 25-39 years).

^ǂmetastatic cancer is cancer that has spread from its original location to another place in the body, representing what is known as stage iii and stage iv cancer diagnoses.  while recent research has revealed that there is a genetic basis for susceptibility or resistance to metastasis, more research is needed to develop a comprehensive understanding of this complex process. applications to the metastatic cancer topic area should focus on the process of metastasis and not the cancer type (i.e.an agnostic interrogation of the process of metastasis).

the fy20 prcrp military health focus areas are listed below:

it is central to the vision and mission of the prcrp that applications address how the proposed research is related to military health, mission readiness, and the cancer health needs of both deployed and non-deployed military personnel, their dependents, veterans, and other military beneficiaries (i.e., family members of retirees).  the fy20 prcrp requires all applications to answer at least one of the following military health focus areas:

• environmental/exposure risk factors associated with cancer
• mission readiness

o    gaps in cancer prevention, early detection/diagnosis, prognosis, and/or treatment that may affect the general population but have a particularly profound impact on the health and well-being of military service members, veterans, and their beneficiaries

o    gaps in quality of life and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military service members, veterans, and their beneficiaries

https://cdmrp.army.mil/funding/prcrp

virtual cancer center director award – letter of intent due july 30, 2020

investigator at or above the level of associate professor (or equivalent); must have a proven publication and funding record in cancer research. 

deputy director must be at or above the level of associate professor (or equivalent); must have a proven publication and funding record in cancer research. deputy director must be at a different institution and must be in a different cancer discipline than the director.

• letter of intent is required.  an invitation to submit a full application is not required.
• supports visionary individuals who are established cancer researchers with a strong record of mentoring and commitment to leadership.
• the prcrp virtual cancer center director award is an opportunity to establish a virtual cancer center focused on fostering the next generation of independent cancer researchers across the spectrum of cancers included under the prcrp.
• director, with deputy director, will oversee the interactive virtual cancer center of early-career investigators (scholars) and their designated career guides, facilitate regular interactive communication among all members, and assess research progress and career progression of the scholars.
• early-career investigators interested in applying to the virtual cancer center should refer to the career development award – cancer center scholar option program announcement.
• maximum funding for the entire period of performance is $1,250,000 for direct costs (plus indirect costs).
• maximum period of performance is 4 years.

career development award – fellow option – letter of intent due july 30, 2020

principal investigator (pi): independent investigators at or above the level of assistant professor or instructor (or equivalent) and within 7 years after completion of their terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline.

career guide: investigators at or above the level of associate professor (or equivalent); must have a proven publication and funding record in cancer research. 

• letter of intent is required.  an invitation to submit a full application is not required.
• supports the addition of new early-career investigators (scholars) to be unique, interactive virtual cancer center focused on fostering the next generation of cancer researcher.
• previous nominal career development funding.
• a career guide – an experiences cancer research with cancer funding – is required.
• the career guide is not required to be at the same institution as the fellow.
• must address at least one of the fy20 prcrp topic areas.
• must address at least one of the fy20 prcrp military health focus areas.
  • preliminary data are not required.
  • clinical trials are not allowed.
  • maximum funding for the entire period of performance is $400,000 for direct costs (plus indirect costs).
  • maximum period of performance is 3 years.

career development award – cancer center scholar option – letter of intent due july 30, 2020

principal investigator (pi):  independent investigators at or above the level of assistant professor or instructor (or equivalent) and within 7 years after completion of their terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline.

career guide:  investigators at or above the level of associate professor (or equivalent); must have a proven publication and funding record in cancer research. 

• letter of intent is required.  an invitation to submit a full application is not required.
• supports the addition of new early-career investigators (scholars) to the unique, interactive virtual cancer center focused on fostering the next generation of independent cancer researchers.
• the scholar shall be required to interact within the virtual cancer center and with the cancer center director and deputy director.
• the scholar option will be required to interact within the virtual cancer center and with the cancer center director and deputy director.
• the scholar option provides intensive mentoring, national networking, and a peer group for junior faculty.
• scholars must demonstrate significant accomplishments.
• scholars whose ability to commit to conducting cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
• a career guide – an experienced cancer researcher with cancer funding – is required.
• the career guide is not required to be at the same institution as the scholar.
• must address at least one of the fy20 prcrp topic areas.
• must address at least one of the fy20 prcrp military health focus areas.
• preliminary data are not required.
• clinical trials are not allowed.
  • maximum funding for the entire period of performance is $800,000 for direct costs (plus indirect costs).
  • maximum period of performance is 4 years.

behavioral health science award – letter of intent due july 30, 2020

independent investigator with a faculty-level appointment (or equivalent).

• letter of intent is required.  an invitation to submit a full application is not required.
• supports innovative research and high-reward studies that span the spectrum of behavioral health science including prevention, quality of life, symptom management, resilience, and psychosocial issues related to cancer diagnosis, treatment, and survivorship.
• emphasis on innovation and military health/impact.
• must address at least one of the fy20 prcrp topic areas.
• must address at least one of the fy20 prcrp military health focus areas.
  • preliminary data may be required if proposing a pilot clinical trial.
  • pilot clinical trials are allowed.
  • maximum funding for the entire period of performance is $1,000,000 for direct costs (plus indirect costs).
  • maximum period of performance is 4 years.

translational team science award – letter of intent due july 30, 2020

at least two, and a maximum of three, pis must partner in one overarching correlative or translational research study.

at least one of the pis is encouraged to be a military or us department of veterans affairs investigator.

• letter of intent is required.  an invitation to submit a full application is not required.
• emphasizes multi-pi, multidisciplinary collaborations.
• supports translational studies associated with an ongoing or completed clinical trial that can lead to a future clinical trial or clinical application in cancer research relevant to service members, their families, and other military beneficiaries.
• not intended to support high throughput screenings, sequencing, etc.
• must address at least one of the fy20 prcrp topic areas.
• must address at least one of the fy20 prcrp military health focus areas.
• preliminary data are required.
• clinical trials are allowed.
• maximum funding for the entire period of performance is $1,500,000 for direct costs (plus indirect costs).
• maximum period of performance is 4 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the fy20 defense appropriations act provides funding to the department of defense peer reviewed cancer research program (prcrp) to support innovative, high-impact cancer research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 prcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

congressionally directed topic areas:  the prcrp appropriation of $110,000,000 will provide funds for research into cancers not addressed in the breast, pancreatic, prostate, ovarian, kidney, lung, melanoma, and rare cancer research programs.  to be considered for funding, applications for the fy20 prcrp must address at least one of the fy20 prcrp topic areas as directed by congress.  research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, melanoma, pancreatic, rare cancer, or ovarian cancer will not be accepted. the inclusion of the individual rare cancer research program shall not prohibit the prcrp from funding the below mentioned cancers or cancer subtypes that may be rare by definition.

the fy20 prcrp topic areas are:

^†as derived from the nci dictionary of cancer terms (http://www.cancer.gov/publications/dictionaries/cancer-terms).  immunotherapy is a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer.  cancers studied under this topic area should be within the scope of the congressional language and the intent of the program announcement(s).

*national cancer institute (nci) definition of adolescents and young adults (https://www.cancer.gov/types/aya) is people between 15-39 years of age.  cancers studied under this topic area should be within the scope of the congressional language and the intent of the program announcement(s). research should be targeted toward children (ages 0-14 years), adolescents (ages 15-24 years), and/or young adults (ages 25-39 years).

^ǂmetastatic cancer is cancer that has spread from its original location to another place in the body, representing what is known as stage iii and stage iv cancer diagnoses.  while recent research has revealed that there is a genetic basis for susceptibility or resistance to metastasis, more research is needed to develop a comprehensive understanding of this complex process. applications to the metastatic cancer topic area should focus on the process of metastasis and not the cancer type (i.e.an agnostic interrogation of the process of metastasis).

the fy20 prcrp military health focus areas are listed below:

it is central to the vision and mission of the prcrp that applications address how the proposed research is related to military health, mission readiness, and the cancer health needs of both deployed and non-deployed military personnel, their dependents, veterans, and other military beneficiaries (i.e., family members of retirees).  the fy20 prcrp requires all applications to answer at least one of the following military health focus areas:

• environmental/exposure risk factors associated with cancer
• mission readiness

o    gaps in cancer prevention, early detection/diagnosis, prognosis, and/or treatment that may affect the general population but have a particularly profound impact on the health and well-being of military service members, veterans, and their beneficiaries

o    gaps in quality of life and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military service members, veterans, and their beneficiaries

https://cdmrp.army.mil/funding/prcrp

idea award – preproposal due may 14,  2020

independent investigator with a faculty-level appointment (or equivalent).

• preproposal is required; application submission is by invitation only.
• supports innovative, untested, high-risk/
  potentially high-reward concepts, theories, paradigms, and/or methods in cancer research relevant to service members, their families, and other military beneficiaries.
• emphasis on innovation and military health/impact.
• must address at least one of the fy20 prcrp topic areas.
• must address at least one of the fy20 prcrp military health focus areas.
• preliminary data are not required.
• clinical trials are not allowed.
• maximum funding for the entire period of performance is $500,000 for direct costs (plus indirect costs).
• maximum period of performance is up to 3 years.

impact award – preproposal due may 14, 2020

independent investigators at or above the level of assistant professor (or equivalent) are eligible to submit an application.

• preproposal is required; application submission is by invitation only.
• supports hypothesis-driven, high impact research.
• encourages applications that support research projects or ideas that specifically focus on critical scientific and clinical cancer issues, which, if successfully addressed, have the potential to make a major impact on one of the fy20 prcrp topic areas.
• must address at least one of the fy20 prcrp topic areas.
• must address at least one of the fy20 prcrp military health focus areas.
• preliminary data are required.
• clinical trials are allowed.
  • maximum funding for the entire period of performance is $1,000,000 for direct costs (plus indirect costs).
  • maximum period of performance is 3 years.

the fy20 defense appropriations act provides funding to the department of defense tick-borne disease research program (tbdrp) to support innovative, high-impact tick-borne disease research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 tbdrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website

applications submitted to the fy20 tbdrp must address one or more of the following focus areas:

• diagnosis:
  • sensitive and specific direct detection diagnostic assay for borrelia and/or other tbd pathogens.  assay should ultimately be amenable for implementation in a typical clinical setting, cost-effective, and rapid (diagnosis in < 24 hours).
  • diagnostic biomarker panel for lyme disease and other tbds that distinguishes tbd infection from other febrile illnesses.
  • approaches for lyme disease or other tbd diagnosis capable of distinguishing active infection and previous exposure, and/or monitoring response to treatment.
  • innovative and new approaches that provide diagnosis for a single or multiple tbd infections from a single sample.
• treatment: 
  • therapeutic strategies for treating acute and persistent tbds.  novel therapeutics and/or non-antibiotic modalities for treating tbds are encouraged.
  • in vitro interrogation of potential treatments designed to mitigate development of long-term sequelae following infection with bacterial, parasitic, or viral tick-borne (tb) agents.
• immunomodulatory approaches to treat the inflammatory response to infection.
• prevention: 
  • drugs, antibodies, or other novel approaches that can be administered and/or utilized prophylactically to prevent human tbd infection.
  • safe and effective human vaccines for tbds.
  • identification, validation, and/or improvement of tick- or reservoir-targeted prevention and control interventions.
  • understanding the ecology of understudied tbd vectors and reservoirs with emphasis on how it relates to human risk.
• pathogenesis:
  • pathogenesis of persistent clinical manifestations associated with lyme disease.
  • immune evasion and/or tolerance of tb pathogens (lyme and/or other tbds).
  • effects of tick sialome on human infection, immune response, disease progression, and pathogen dissemination.
  • tb infections and co-infections (simultaneous or sequential) and their effects on human disease severity, the local and systemic immune response, and/or pathogen synergy and competition.
  • red meat allergy (allergic response to alpha-gal).

https://cdmrp.army.mil/funding/tbdrp

career development award – preproposal due may 27, 2020

principal investigator (pi): 

early-career research scientist, physician scientist, or other qualified clinical scientist, within 10 years of completion of his/her terminal degree (excluding time in residency or on family medical leave) at the time of submission, working to become independent investigators who exhibit a strong desire to pursue careers in tick-borne disease research; time spent as a postdoctoral fellow is not excluded

mentor:  independent investigators at or above the level of associate professor (or equivalent); must have a recent (last 5years), proven funding and publication record in tick-borne disease research.

the pi and mentor do not need to be located with the same organization.

• to fund early-career investigators to conduct impactful research under the mentorship of an experienced tick-borne disease researcher.
• career development plan is required.  plan should be prepared with appropriate guidance from the mentor, should clearly articulate a strategy for acquiring the necessary skills, competence, and expertise to establish a career at the forefront of tick-borne disease research, and should outline how the pi will gain experience in tick-borne disease research.  pi’s institution must demonstrate a commitment to the pi through a minimum of 75% protected research time for tick-borne disease research.  the application must include clearly stated plans for interactions and communication coordination between the pi and mentor.
• preliminary data is encouraged, but not required.
• clinical trials are not allowed.
• maximum funding of $300k for direct costs (plus indirect costs)
• maximum period of performance is 3 years

idea development award – preproposal is due may 27, 2020

independent investigators at or above the level of assistant professor (or equivalent)

• to fund research that could lead to impactful discoveries or major advancements that will accelerate progress in improving outcomes for individuals affected by lyme diseases and/or other tick-borne illnesses
• research should be conceptually innovative, exhibit high levels of creativity, or challenge existing research paradigms.
• applications must describe the short- and long-term impact of the proposed research, as well as the public health burden of the diseases being addressed.
• preliminary data is encouraged, but not required.
• clinical trials are not allowed; human studies/clinical research are permitted.
• maximum funding of $600k for direct costs (plus indirect costs)
• maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the tbdrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org